Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
Megan M. Tu(University of Colorado Cancer Center), Dan Theodorescu(University of Arizona), Garrett M. Dancik(Eastern Connecticut State University), Robert T. Jones(MedStar Franklin Square Medical Center), James C. Costello(University of Colorado Cancer Center), Jason E. Duex(Cedars-Sinai Medical Center), Bogdan Czerniak(The University of Texas MD Anderson Cancer Center), Hany Abdel-Hafiz(University of Arizona), Jonathan Kaye(Cedars-Sinai Medical Center), Katelyn J. Hoff(University of Colorado Anschutz Medical Campus), Beth A. Jirón Tamburini(University of Colorado Denver), Annie Jean(University of Colorado Anschutz Medical Campus), Ana Chauca-Diaz(University of Colorado Anschutz Medical Campus)
Cited by 170
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
|Proceedings of the National Academy of Sciences|2013|1.4k
Advances in bladder cancer biology and therapy
|Nature reviews. Cancer|2020|783